Research

Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line

Marius Stiefelhagen^1,2 , Leopold Sellner¹ , Jürgen A Kleinschmidt³ , Anna Jauch⁴ , Stephanie Laufs⁵ , Frederik Wenz⁶ , W Jens Zeller¹ , Stefan Fruehauf^2,7 and Marlon R Veldwijk^1,6

¹  Department G402, Pharmacology of Cancer Treatment, German Cancer Research Center, INF 280, D-69120, Heidelberg, Germany

²  Department of Internal Medicine V, University of Heidelberg, INF 410, D-69120, Heidelberg, Germany

³  Department F010, Applied Tumor Virology, German Cancer Research Center, INF 242, D-69120, Heidelberg, Germany

⁴  Institute of Human Genetics Heidelberg, University of Heidelberg, INF 366, D-69120 Heidelberg, Germany

⁵  Department G360, Molecular Oncology of Solid Tumors, German Cancer Research Center, INF 580, D-69120, Heidelberg, Germany

⁶  Department of Radiation Oncology, Mannheim Medical Center, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135, Mannheim, Germany

⁷  Center for Tumor Diagnostics and Therapy, Paracelsus-Klinik, Am Natruper Holz 69, D-49046, Osnabrück, Germany

author email corresponding author email

Genetic Vaccines and Therapy 2008, 6:12doi:10.1186/1479-0556-6-12

Published:	12 September 2008

Abstract

Background

For many promising target cells (e.g.: haematopoeitic progenitors), the susceptibility to standard adeno-associated viral (AAV) vectors is low. Advancements in vector development now allows the generation of target cell-selected AAV capsid mutants.

Methods

To determine its suitability, the method was applied on a chronic myelogenous leukaemia (CML) cell line (K562) to obtain a CML-targeted vector and the resulting vectors tested on leukaemia, non-leukaemia, primary human CML and CD34⁺ peripheral blood progenitor cells (PBPC); standard AAV2 and a random capsid mutant vector served as controls.

Results

Transduction of CML (BV173, EM3, K562 and Lama84) and AML (HL60 and KG1a) cell lines with the capsid mutants resulted in an up to 36-fold increase in CML transduction efficiency (K562: 2-fold, 60% ± 2% green fluorescent protein (GFP)⁺ cells; BV173: 9-fold, 37% ± 2% GFP⁺ cells; Lama84: 36-fold, 29% ± 2% GFP⁺ cells) compared to controls. For AML (KG1a, HL60) and one CML cell line (EM3), no significant transduction (<1% GFP⁺ cells) was observed for any vector. Although the capsid mutant clone was established on a cell line, proof-of-principle experiments using primary human cells were performed. For CML (3.2-fold, mutant: 1.75% ± 0.45% GFP⁺ cells, p = 0.03) and PBPC (3.5-fold, mutant: 4.21% ± 3.40% GFP⁺ cells) a moderate increase in gene transfer of the capsid mutant compared to control vectors was observed.

Conclusion

Using an AAV random peptide library on a CML cell line, we were able to generate a capsid mutant, which transduced CML cell lines and primary human haematopoietic progenitor cells with higher efficiency than standard recombinant AAV vectors.